GOOD JENNIFER L 4

What Happened

• Jennifer L. Good, President, CEO and a director of Trevi Therapeutics (TRVI), was granted a derivative award on February 19, 2026 covering 675,000 shares of common stock.
• The Form 4 reports the acquisition price as $0 (award/grant), i.e., this was an option/award grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-19; transaction type: A (award/grant); reported acquisition price: $0 (derivative).
• Shares underlying the award: 675,000 optioned shares.
• Shares owned following the transaction: not specified in the information provided in this summary (check the full Form 4 for total holdings).
• Footnote: The option vests in equal monthly installments through February 19, 2030, subject to continued service (per footnote F1).
• Filing timeliness: Form filed 2026-02-20 for a 2026-02-19 transaction — appears to be timely (filed next business day).

Context

• This was a grant of options/awarded equity (a compensation/retention grant), not an immediate purchase or sale. No shares were sold or exercised at the time of this filing.
• Such awards typically vest over time and are conditioned on continued service; they are common for executives and are not direct market buys or sells.